摘要
目的:了解我院治疗恶性肿瘤骨转移药的应用现状及趋势。方法:对我院2006～2009年治疗恶性肿瘤骨转移药的应用情况进行统计、分析。结果:我院治疗恶性肿瘤骨转移药的用量总体呈不断增长趋势,帕米膦酸钠一直稳居销售金额排序的第1位,约占总销售金额的80%。用药频度最高的是帕米膦酸钠(国产),增长最快的是氯膦酸钠,由2006年的0.67%增至2009年的31.68%。日用药费用排序在2006～2009年未发生改变。结论:我院治疗恶性肿瘤骨转移药应用较合理,由价格依从逐渐过渡为疗效依从。
OBJECTIVE：To investigate the status quo and tendency of the utilization of drug for bony metastasis cancer in our hospital. METHODS：The utilization of drug for bony metastasis cancer in our hospital from 2006 to 2009 was analyzed statistically. RESULTS：The total amount of the drug for bony metastasis cancer had been increasing. Pamidronate took up the first place of the consumption sum list and accounted for 80% of total consumption sum. Top one drug in the list of DDDs was domestical pamidronate. Utilization rate of disodium clodronate increased form 0.67% in 2006 to 31.68% in 2009. The order of DDC had not changed during 2006～2009. CONCLUSION：In recent year the drug for bony metastasis cancer has been rational and has become curative effect-oriented rather than price-oriented.
出处
《中国药房》
CAS
CSCD
北大核心
2010年第14期1277-1279,共3页
China Pharmacy
